Skip to main content
Top
Published in: Cost Effectiveness and Resource Allocation 1/2011

Open Access 01-12-2011 | Research

Insomnia - treatment pathways, costs and quality of life

Authors: Guy W Scott, Helen M Scott, Karyn M O'Keeffe, Philippa H Gander

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2011

Login to get access

Abstract

Background

Insomnia is perhaps the most common sleep disorder in the general population, and is characterised by a range of complaints around difficulties in initiating and maintaining sleep, together with impaired waking function. There is little quantitative information on treatment pathways, costs and outcomes. The aims of this New Zealand study were to determine from which healthcare practitioners patients with insomnia sought treatment, treatment pathways followed, the net costs of treatment and the quality of life improvements obtained.

Methods

The study was retrospective and prevalence based, and was both cost effectiveness (CEA) and a cost utility (CUA) analysis. Micro costing techniques were used and a societal analytic perspective was adopted. A deterministic decision tree model was used to estimate base case values, and a stochastic version, with Monte Carlo simulation, was used to perform sensitivity analysis. A probability and cost were attached to each event which enabled the costs for the treatment pathways and average treatment cost to be calculated. The inputs to the model were prevalence, event probabilities, resource utilisations, and unit costs. Direct costs and QALYs gained were evaluated.

Results

The total net benefit of treating a person with insomnia was $482 (the total base case cost of $145 less health costs avoided of $628). When these results were applied to the total at-risk population in New Zealand additional treatment costs incurred were $6.6 million, costs avoided $28.4 million and net benefits were $21.8 million. The incremental net benefit when insomnia was "successfully" treated was $3,072 per QALY gained.

Conclusions

The study has brought to light a number of problems relating to the treatment of insomnia in New Zealand. There is both inadequate access to publicly funded treatment and insufficient publicly available information from which a consumer is able to make an informed decision on the treatment and provider options. This study suggests that successful treatment of insomnia leads to direct cost savings and improved quality of life.
Appendix
Available only for authorised users
Literature
1.
go back to reference American Academy of Sleep Medicine: The international classification of sleep disorders: Diagnostic and coding manual (ICSD-2). 2nd edition. Westchester, IL: American Academy of Sleep Medicine; 2005. American Academy of Sleep Medicine: The international classification of sleep disorders: Diagnostic and coding manual (ICSD-2). 2nd edition. Westchester, IL: American Academy of Sleep Medicine; 2005.
2.
go back to reference American Psychiatric Association: Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th edition. Washington, DC: American Psychiatric Association; 2000. American Psychiatric Association: Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th edition. Washington, DC: American Psychiatric Association; 2000.
3.
go back to reference Morin CM, LeBlanc M, Daley M, Gregoire JP, Merette C: Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Medicine 2006, 7: 123–130. 10.1016/j.sleep.2005.08.008PubMedCrossRef Morin CM, LeBlanc M, Daley M, Gregoire JP, Merette C: Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Medicine 2006, 7: 123–130. 10.1016/j.sleep.2005.08.008PubMedCrossRef
4.
go back to reference Kyle SD, Morgan K, Espie CA: Insomnia and health-related quality of life. Sleep Medicine Reviews 2010, 14: 69–82. 10.1016/j.smrv.2009.07.004PubMedCrossRef Kyle SD, Morgan K, Espie CA: Insomnia and health-related quality of life. Sleep Medicine Reviews 2010, 14: 69–82. 10.1016/j.smrv.2009.07.004PubMedCrossRef
5.
go back to reference Ohayon MM: Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med Rev 2002, 6: 97–111. 10.1053/smrv.2002.0186PubMedCrossRef Ohayon MM: Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med Rev 2002, 6: 97–111. 10.1053/smrv.2002.0186PubMedCrossRef
6.
go back to reference Paine SJ, Gander PH, Harris R: Who reports insomnia? Relationships with age, sex, ethnicity, and socioeconomic deprivation. Sleep 2004, 27: 1163–1169.PubMed Paine SJ, Gander PH, Harris R: Who reports insomnia? Relationships with age, sex, ethnicity, and socioeconomic deprivation. Sleep 2004, 27: 1163–1169.PubMed
7.
go back to reference Paine SJ, Gander PH, Harris RB: Prevalence and consequences of insomnia in New Zealand: disparities between Maori and non-Maori. Aust N Z J Public Health 2005, 29: 22–28. 10.1111/j.1467-842X.2005.tb00743.xPubMedCrossRef Paine SJ, Gander PH, Harris RB: Prevalence and consequences of insomnia in New Zealand: disparities between Maori and non-Maori. Aust N Z J Public Health 2005, 29: 22–28. 10.1111/j.1467-842X.2005.tb00743.xPubMedCrossRef
8.
go back to reference Sleep/Wake Research Centre Massey University: Data on file. Wellington: Massey University; 2011. Sleep/Wake Research Centre Massey University: Data on file. Wellington: Massey University; 2011.
9.
go back to reference Hillman DR, Murphy AS, Pezzullo L: The economic cost of sleep disorders. Sleep 2006, 29: 299–305.PubMed Hillman DR, Murphy AS, Pezzullo L: The economic cost of sleep disorders. Sleep 2006, 29: 299–305.PubMed
10.
go back to reference Leger D, Levy E, Paillard M: The direct costs of insomnia in France. Sleep 1999, S394-s401. Leger D, Levy E, Paillard M: The direct costs of insomnia in France. Sleep 1999, S394-s401.
11.
go back to reference OECD: OECD Factbook 2008: Economic, Environmental and Social Statistics. Organisation for Economic Co-operation and Development; 2008. OECD: OECD Factbook 2008: Economic, Environmental and Social Statistics. Organisation for Economic Co-operation and Development; 2008.
12.
go back to reference Walsh JK, Engelhardt CL: The direct economic costs of insomnia in the United States for 1995. Sleep 1999,22(Suppl 2):S386–393.PubMed Walsh JK, Engelhardt CL: The direct economic costs of insomnia in the United States for 1995. Sleep 1999,22(Suppl 2):S386–393.PubMed
13.
go back to reference Chilcott LA, Shapiro CM: The socioeconomic impact of insomnia. An overview. PharmacoEconomics 1996,10(Suppl 1):1–14.PubMedCrossRef Chilcott LA, Shapiro CM: The socioeconomic impact of insomnia. An overview. PharmacoEconomics 1996,10(Suppl 1):1–14.PubMedCrossRef
14.
go back to reference Ozminkowski RJ, Wang S, Walsh JK: The direct and indirect costs of untreated insomnia in adults in the United States (Provisional record). Sleep 2007, 263–273. Ozminkowski RJ, Wang S, Walsh JK: The direct and indirect costs of untreated insomnia in adults in the United States (Provisional record). Sleep 2007, 263–273.
15.
go back to reference Susman E: APSS: extra health cost of insomnia reaches $3,2000 ann employee. MedPage Today 2007. Susman E: APSS: extra health cost of insomnia reaches $3,2000 ann employee. MedPage Today 2007.
16.
go back to reference Novak M, Mucsi I, Shapiro CM, Rethelyi J, Kopp MS: Increased utilization of health services by insomniacs--an epidemiological perspective. J Psychosom Res 2004, 56: 527–536. 10.1016/j.jpsychores.2004.02.007PubMedCrossRef Novak M, Mucsi I, Shapiro CM, Rethelyi J, Kopp MS: Increased utilization of health services by insomniacs--an epidemiological perspective. J Psychosom Res 2004, 56: 527–536. 10.1016/j.jpsychores.2004.02.007PubMedCrossRef
17.
go back to reference Kapur VK, Redline S, Nieto FJ, Young TB, Newman AB, Henderson JA: The relationship between chronically disrupted sleep and healthcare use. Sleep 2002, 25: 289–296.PubMed Kapur VK, Redline S, Nieto FJ, Young TB, Newman AB, Henderson JA: The relationship between chronically disrupted sleep and healthcare use. Sleep 2002, 25: 289–296.PubMed
18.
go back to reference Leger D, Guilleminault C, Bader G, Levy E, Paillard M: Medical and socio-professional impact of insomnia. Sleep 2002, 25: 625–629.PubMed Leger D, Guilleminault C, Bader G, Levy E, Paillard M: Medical and socio-professional impact of insomnia. Sleep 2002, 25: 625–629.PubMed
19.
go back to reference Hatoum HT, Kania CM, Kong SX, Wong JM, Mendelson WB: Prevalence of insomnia: a survey of the enrollees at five managed care organizations. The American journal of managed care 1998, 4: 79–86.PubMed Hatoum HT, Kania CM, Kong SX, Wong JM, Mendelson WB: Prevalence of insomnia: a survey of the enrollees at five managed care organizations. The American journal of managed care 1998, 4: 79–86.PubMed
20.
go back to reference Simon GE, VonKorff M: Prevalence, burden, and treatment of insomnia in primary care. The American journal of psychiatry 1997, 154: 1417–1423.PubMedCrossRef Simon GE, VonKorff M: Prevalence, burden, and treatment of insomnia in primary care. The American journal of psychiatry 1997, 154: 1417–1423.PubMedCrossRef
21.
go back to reference Godet-Cayre V, Pelletier-Fleury N, Le Vaillant M, Dinet J, Massuel M-A, Leger D: Insomnia and absenteeism at work. Who pays the cost? Sleep 2006, 29: 179–184.PubMed Godet-Cayre V, Pelletier-Fleury N, Le Vaillant M, Dinet J, Massuel M-A, Leger D: Insomnia and absenteeism at work. Who pays the cost? Sleep 2006, 29: 179–184.PubMed
22.
go back to reference Katz DA, McHorney CA: The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002, 51: 229–235.PubMed Katz DA, McHorney CA: The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002, 51: 229–235.PubMed
23.
go back to reference Leger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C: SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosomatic Medicine 2001, 63: 49–55.PubMedCrossRef Leger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C: SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosomatic Medicine 2001, 63: 49–55.PubMedCrossRef
24.
go back to reference Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB: Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. PharmacoEconomics 1998, 14: 629–637. 10.2165/00019053-199814060-00004PubMedCrossRef Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB: Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. PharmacoEconomics 1998, 14: 629–637. 10.2165/00019053-199814060-00004PubMedCrossRef
25.
go back to reference Institute of Medicine of the National Academies Committee on Sleep Medicine and Research Board on Health Sciences Policy: Functional and economic impact of sleep loss and sleep-related disorders. In Sleep disorders and sleep deprivation: an unmet public health problem. Edited by: Colten HR, Altevogt BM. Washington, DC: National Academies Press; 2006. Institute of Medicine of the National Academies Committee on Sleep Medicine and Research Board on Health Sciences Policy: Functional and economic impact of sleep loss and sleep-related disorders. In Sleep disorders and sleep deprivation: an unmet public health problem. Edited by: Colten HR, Altevogt BM. Washington, DC: National Academies Press; 2006.
26.
go back to reference Akerstedt T, Fredlund P, Gillberg M, Jansson B: A prospective study of fatal occupational accidents -- relationship to sleeping difficulties and occupational factors. J Sleep Res 2002, 11: 69–71. 10.1046/j.1365-2869.2002.00287.xPubMedCrossRef Akerstedt T, Fredlund P, Gillberg M, Jansson B: A prospective study of fatal occupational accidents -- relationship to sleeping difficulties and occupational factors. J Sleep Res 2002, 11: 69–71. 10.1046/j.1365-2869.2002.00287.xPubMedCrossRef
27.
go back to reference Leger D, Massuel MA, Metlaine A: Professional correlates of insomnia. Sleep 2006, 29: 171–178.PubMed Leger D, Massuel MA, Metlaine A: Professional correlates of insomnia. Sleep 2006, 29: 171–178.PubMed
28.
go back to reference National Sleep Foundation: 2008 Sleep in America Poll. Washington, DC: National Sleep Foundation; 2008. National Sleep Foundation: 2008 Sleep in America Poll. Washington, DC: National Sleep Foundation; 2008.
29.
go back to reference Stinson K, Tang NK, Harvey AG: Barriers to treatment seeking in primary insomnia in the United Kingdom: A cross-sectional perspective. Sleep 2006, 29: 1643–1646.PubMed Stinson K, Tang NK, Harvey AG: Barriers to treatment seeking in primary insomnia in the United Kingdom: A cross-sectional perspective. Sleep 2006, 29: 1643–1646.PubMed
30.
go back to reference O'Keeffe KM, Gander PH, Scott WG, Scott HM: Insomnia treatment in New Zealand. New Zealand Medical Journal 2011, in press. O'Keeffe KM, Gander PH, Scott WG, Scott HM: Insomnia treatment in New Zealand. New Zealand Medical Journal 2011, in press.
32.
go back to reference Devlin NJ, Hanson P, Kind P: The health state preferences and logical inconsistencies of New Zealanders: A tail of two tariffs. University of York Centre for Health Economics Discussion paper 2000. Devlin NJ, Hanson P, Kind P: The health state preferences and logical inconsistencies of New Zealanders: A tail of two tariffs. University of York Centre for Health Economics Discussion paper 2000.
33.
go back to reference Pharmaceutical Management Agency of New Zealand: Zopiclone. New Zealand Pharmaceutical Schedule 2009, 16: 128. Pharmaceutical Management Agency of New Zealand: Zopiclone. New Zealand Pharmaceutical Schedule 2009, 16: 128.
37.
go back to reference Palisade Corporation: @ Risk version 4.5 Risk analysis and simulation add-in for Microsoft Excel. Newfield NY; 2004. Palisade Corporation: @ Risk version 4.5 Risk analysis and simulation add-in for Microsoft Excel. Newfield NY; 2004.
39.
go back to reference Pharmaceutical Management Agency of New Zealand: Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. Final version 2 edition. Wellington: Pharmaceutical Management Agency of New Zealand; 2007. Pharmaceutical Management Agency of New Zealand: Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. Final version 2 edition. Wellington: Pharmaceutical Management Agency of New Zealand; 2007.
41.
go back to reference New Zealand Ministry of Health: Health expenditure trends in New Zealand 1998–2008. Wellington: NZ Ministry of Health; 2010. New Zealand Ministry of Health: Health expenditure trends in New Zealand 1998–2008. Wellington: NZ Ministry of Health; 2010.
Metadata
Title
Insomnia - treatment pathways, costs and quality of life
Authors
Guy W Scott
Helen M Scott
Karyn M O'Keeffe
Philippa H Gander
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2011
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/1478-7547-9-10

Other articles of this Issue 1/2011

Cost Effectiveness and Resource Allocation 1/2011 Go to the issue